Julio Rosenstock, MD, FACE, joined the American Diabetes Association’s Diabetes Core Update podcast to discuss propound results from a recently published JAMA article, “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes.” The study indicated that once weekly tirzepatide with insulin glargine may have the potential to change the standard of care for adults with type 2 diabetes taking basal insulin.
Additionally, Dr. Rosenstock was interviewed in several recent episodes about publications in JAMA, The Lancet, and the New England Journal of Medicine.
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in T2D: https://jamanetwork.com/journals/jama/article-abstract/2810386
- Retatrutide for T2D: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
- Weekly Icodec for T2D: https://www.nejm.org/doi/10.1056/NEJMoa2303208